USP22 and breast carcinoma: Interestingly, heterozygous Usp22 deletion in mammary carcinoma cells was sufficient to significantly increase disease-free survival of MMTV-Erbb2 animals (median survival: 209 days), implying that the reduction of USP22 levels is sufficient to impair the oncogenic properties of HER2+-BC.